SAN FRANCISCO, CA--(Marketwired - November 15, 2016) - By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals Corp. (NASDAQ: RXII) has expanded its reach into the "high-value" field of immune-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future.
Included in this article is: RXi Pharmaceuticals Corp.
Keith Markey of Griffin Securities called the RXi Pharmaceuticals Corp. acquisition option "an attractive opportunity" in a research report released following the Oct. 12 announcement.
"Given the interest in cellular immunotherapies and the proven ability of checkpoint inhibitors to enhance T cell activity, RXi's relatively small investments may well pay off handsomely, particularly if the sd-rxRNA pretreatment obviates the need for expensive checkpoint inhibitors," Markey wrote.
RXi's self-delivering RNAi (sd-rxRNA) compounds have the ability to "'silence' or down-regulate the expression of a specific gene that may be overexpressed in a disease condition," according to the company. Thus far, the partnership with MirImmune has shown in cell cultures that the technology can enhance inhibition of checkpoints such as PD-1, and has the potential to improve the efficacy of innovative immunotherapies such as CAR T-cells.
Continue reading this article: Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
RXi Pharmaceuticals Corp. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena